Publications by authors named "Takuya Hemmi"

Claim this Profile
S
Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1.
Hisano Yajima, Yuki Anraku, Yu Kaku, Kanako Terakado Kimura, Arnon Plianchaisuk, Takuya Hemmi

Nat Commun· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
Takuhiro Sonoyama, Satoshi Iwata, Masaharu Shinkai, Naoko Iwata-Yoshikawa, Nozomi Shiwa-Sudo, Takuya Hemmi

Vaccine· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralization.
Sho Miyamoto, Takeshi Arashiro, Akira Ueno, Takayuki Kanno, Shinji Saito, Takuya Hemmi

iScience· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology.
Takuya Hemmi, Akira Ainai, Takao Hashiguchi, Minoru Tobiume, Takayuki Kanno

Vaccine· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.
Sho Miyamoto, Takeshi Arashiro, Yu Adachi, Saya Moriyama, Hitomi Kinoshita, Takuya Hemmi

Med· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection.
Naoko Iwata-Yoshikawa, Nozomi Shiwa, Tsuyoshi Sekizuka, Kaori Sano, Akira Ainai, Takuya Hemmi

Sci Adv· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Guided Creation of an Anti-HA Stalk Antibody F11 Derivative That Neutralizes Both F11-Sensitive and -Resistant Influenza A(H1N1)pdm09 Viruses.
Osamu Kotani, Yasushi Suzuki, Shinji Saito, Akira Ainai, Akira Ueno, Takuya Hemmi

Viruses· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis